The novel arylamidine T-2307 maintains in vitro and in vivo activity against echinocandin-resistant Candida albicans

Antimicrob Agents Chemother. 2015 Feb;59(2):1341-3. doi: 10.1128/AAC.04228-14. Epub 2014 Dec 1.

Abstract

We evaluated the in vitro and in vivo activities of the investigational arylamidine T-2307 against echinocandin-resistant Candida albicans. T-2307 demonstrated potent in vitro activity, and daily subcutaneous doses between 0.75 and 6 mg/kg of body weight significantly improved survival and reduced fungal burden compared to placebo control and caspofungin (10 mg/kg/day) in mice with invasive candidiasis caused by an echinocandin-resistant strain. Thus, T-2307 may have potential use in the treatment of echinocandin-resistant C. albicans infections.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, Non-P.H.S.
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Amidines / pharmacology*
  • Animals
  • Antifungal Agents / pharmacology*
  • Antifungal Agents / therapeutic use*
  • Candida albicans / drug effects
  • Candida albicans / pathogenicity*
  • Candidiasis / drug therapy
  • Drug Resistance, Fungal
  • Echinocandins / pharmacology*
  • Echinocandins / therapeutic use*
  • Male
  • Mice
  • Mice, Inbred ICR
  • Microbial Sensitivity Tests

Substances

  • Amidines
  • Antifungal Agents
  • Echinocandins
  • T-2307